Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label, treat-to-target…

Overview of attention for article published in The Lancet, October 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (93rd percentile)

Mentioned by

news: 34 news outlets
blogs: 3 blogs
twitter: 41 X users
facebook: 1 Facebook page

wikipedia: 2 Wikipedia pages
video: 1 YouTube creator
guideline: 2 clinical guideline sources
podcasts: 2 podcasts

Readers on

mendeley: 104 Mendeley

So far, Altmetric has seen 42 X posts from 41 X users, with an upper bound of 1,148,128 followers.

@shinyaku_online そうなんですね。前に読んだのがアウィクリと似たような評価になってましたので…低血糖リスクが少ないなら楽しみです。 https://t.co/WUDBpUvdpD

@PracticalDeeb Similar things happened for T1D's in Novo's ONWARD6 trial of icodec vs degludec. The once a week shot increased hypoglycaemic episodes. See here: https://t.co/cAefnjT8JV

RT @muscle_penguin_: イコデクの過去のまとめ@dr_ukio先生ツイートよりグラルギン、トレシーバとCGMで見ても同等 https://t.co/7bu1KmNChy メタ解析でも同様 https://t.co/kVCOSAbIwK 定常状態は3-4…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 38 additional X posts.